Factors including hospital consolidation and increasing price transparency bring growing pricing pressure to medtech manufacturers. In this context, more manufacturers are considering new approaches to value-based pricing to maximize opportunity while minimizing risk, according to this expert column from Matthew Majewski and Kira Gordon.
Gene therapy competitive dynamics: Winner takes all?
This article was originally published in Cell & Gene. It has also been published in Cell & Gene‘s sister publication, OutSourced Pharama. With many gene...